Rajkumar Sugumaran, MD
Cardiovascular Disease · Phoenix, AZNPI 1184840506
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $769,517 of the $957,253 with a category attached, or 80.4%. 54 manufacturers reported payments, led by Amgen at 33.4% of the total. Among cardiovascular disease clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,739 payments — averaging $550.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$319K
- Boehringer Ingelheim$160K
- Lilly USA, LLC$138K
- Novo Nordisk$120K
- Novartis$64K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$47K
- plus $109K from 48 others
Across 2 payments — averaging $1397.82 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$3K
What the payments were for
- Consulting fees$30,8013%
- Speaking & faculty fees$769,51780%
- Travel & lodging$89,0739%
- Food & beverage$46,0365%
- Education$2960%
- Charitable contribution$1,6150%
- Other$19,9172%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Repatha$296,913
- JARDIANCE$272,162
- Wegovy$90,458
- ENTRESTO$55,955
- LifeVest$44,131
- WATCHMAN Access System$29,000
- Auryon Laser System 100-120 Vac$19,917
- VERQUVO$15,993
- Kerendia$10,337
- Watchman$10,129
- Optitorque$7,096
- Heartrail$7,096
- TR Band$7,096
- Glidesheath$7,096
- LEQVIO$2,839
- Korlym$2,538
- WatchPATONE$1,734
- (6574) Coronary Other$1,209
- TherOx DS2 Console$1,182
- Catheter$1,182
How this compares
$957,253 in reported general payments places this provider in the 95th percentile of 423 cardiovascular disease providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 283 | $396,816 |
| Repatha SureclickEvolocumab | 378 | $278,416 |
| JardianceEmpagliflozin | 164 | $234,009 |
| XareltoRivaroxaban | 138 | $210,228 |
| EntrestoSacubitril/Valsartan | 73 | $106,890 |
| OzempicSemaglutide | 69 | $77,135 |
| FarxigaDapagliflozin Propanediol | 52 | $51,581 |
| Praluent PenAlirocumab | 51 | $28,861 |
| Repatha SyringeEvolocumab | 26 | $20,181 |
| NexletolBempedoic Acid | 17 | $19,406 |
| BrilintaTicagrelor | 18 | $16,780 |
| KerendiaFinerenone | 14 | $13,694 |
| VascepaIcosapent Ethyl | 13 | $11,415 |
| Repatha PushtronexEvolocumab | 13 | $9,811 |
| Ranolazine ErRanolazine | 36 | $6,480 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $163 | $396,816283 claims |
| Boehringer IngelheimJardiance | $160,464 | $234,009164 claims |
| Johnson & JohnsonXarelto | $681 | $210,228138 claims |
| NovartisEntresto | $63,780 | $106,89073 claims |
| Novo NordiskOzempic | $119,891 | $77,13569 claims |
| AstraZenecaFarxiga, Brilinta | $913 | $68,36070 claims |
| Esperion Therapeutics, Inc.Nexletol | $329 | $19,40617 claims |
| BayerKerendia | $10,736 | $13,69414 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 423 cardiovascular disease providers in Arizona.
Other cardiovascular disease in Phoenix
- Ashish GuptaPhoenix$1.1M
- Tabitha MoePhoenix$182K
- Jesse SethiPhoenix$150K
- Robert ScottPhoenix$106K
- Kethes WaramPhoenix$66K
- Ayman JamalPhoenix$42K
- Sarika DesaiPhoenix$41K
- Suzanne SorofPhoenix$29K
- Namit RohantPhoenix$25K
- Venkataramanan GangadharanPhoenix$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.